



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
Sheet	1	of	1	Attorney Docket Number	VASG-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BT	WO 2004/080425 A	09-23-2004	Vasgene Therapeutics, Inc.		
	BU	WO 2004/024773 A	03-25-2004	The Queen Elizabeth Hospital		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CE1	Santa Cruz Biotechnology, Inc., "EphB4 (N-19): sc-7285", retrieved from the Internet: URL: http://www.genetimes.com.cn/support/pd-f-ds/7200-7299/sc-7285.pdf (1999)	
	CF1	Sinha, et al., "Expression of EphB4 in head and neck squamous cell carcinoma" Ear, Nose and Throat Journal, 82(11), pages 866-870 & 887 (2003)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	8/11/06
-----------------------	--	--------------------	---------

8950868_1




PTO/SB/08a/b (07-05)


Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/800350
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
(Use as many sheets as necessary)				Attorney Docket Number	VASG-P01-002
Sheet	1	of	6		


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AE	US-2002/0136726	09-26-2002	Anderson et al.	
	AF	US-5,824,303	10-20-1998	Bartley et al.	
	AG	US-6,514,497	02-04-2003	Briskin et al.	
	AH	US-5,795,734	08-18-1998	Flanagan et al.	
	AI	US-5,770,599	06-23-1998	Gibson	
	AJ	US-6,440,954	08-27-2002	Haber et al.	
	AK	US-5,512,591	04-30-1996	Halperin et al.	
	AL	US-6,015,711	01-18-2000	Olson et al.	
	AM	US-6,579,683	06-17-2003	Wang et al.	
	AN	US-6,887,674	05-03-2005	Wang et al.	
	AO	US-6,916,625	07-12-2005	Wang et al.	
	AP	US-2005/0204412	09-15-2005	Wang et al.	
	AQ	US-6,864,227	03-08-2005	Wang et al.	
	AR	US-2006/0035328	02-16-2006	Wang et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BV	WO 98/43960	10-08-1998	American Cyanamid Company		
	BW	WO 94/11020	05-26-1994	Amgen Inc.		
	BX	WO 96/23000	08-01-1996	Amgen Inc.		
	BY	WO 96/36713	11-21-1996	Amgen Inc.		
	BZ	WO 97/23629	07-03-1997	Amrad Operations PTY. Ltd.		
	BA1	EP 633 315-A2	01-11-1995	C.I.E.M.A.T.		
	BB1	WO 99/52541	10-21-1999	California Institute of Technology		
	BC1	WO 98/45331	10-15-1998	Genentech, Inc.		
	BD1	WO 97/44453	11-27-1997	Genentech, Inc.		
	BE1	WO 97/09427	03-13-1997	Genentech, Inc.		
	BF1	WO 94/10202	05-11-1994	Genentech, Inc.		
	BG1	WO 96/13518	05-09-1996	Genentech, Inc.		
	BH1	WO 99/17796	04-15-1999	Leukosite, Inc.		
	BI1	WO 2004/091375	10-28-2004	Medimmune, Inc.		
	BJ1	WO 2005/048917	06-02-2005	Medimmune, Inc.		
	BK1	WO 2005/051307	06-09-2005	Medimmune, Inc.		
	BL1	WO 03/094859	11-20-2003	Medimmune, Inc.		
	BM1	WO 96/09384	03-28-1996	President and Fellows of Harvard College		
	BN1	WO 2004/014292	02-19-2004	Purdue Research Foundation		


Examiner Signature		Date Considered	8.11.06
-----------------------	--	--------------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/800350
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
(Use as many sheets as necessary)				Attorney Docket Number	VASG-P01-002
Sheet	2	of	6		

	BO1	WO 96/03043	02-08-1996	Rutgers, the State University of New Jersey	
	BP1	WO 93/00425	01-07-1993	The Walter and Eliza Hall Institute of Medical Research	
	BQ1	EP 0999 278	05-10-2000	Universite ParisVII	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CG1	Adams, R.H., et al., "Eph Receptors and Ephrin Ligands: Essential Mediators of Vascular Development," <i>Trends. Cardiovasc. Med.</i> , 10:183-188 (2000).			
	CH1	Andres, A. C. et al., "Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis," <i>Oncogene</i> , 9:1461-1467 (1994).			
	CI1	Asahara, T. et al., "Isolation of Putative Progenitor Endothelial Cells for Angiogenesis," <i>Science</i> , 275:964-967 (1997).			
	CJ1	Batlle, E., et al., "EphB receptor activity suppresses colorectal cancer progression," <i>Nature</i> , 435(23):1126-1130 (2005).			
	CK1	Bennett, B. D. et al., "Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1866-1870 (1995).			
	CL1	Bennett, B.D., et al., "Cloning and Characterization of HTK, a Novel Transmembrane Tyrosine Kinase of the EPH Subfamily," <i>The Journal of Biological Chemistry</i> , 269(19):14211-14218 (1994).			
	CM1	Bergemann, A. D. et al., "ELF-2, a New Member of the Eph Ligand Family Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites," <i>Molecular and Cellular Biology</i> , 15(9):4921-4929 (1995).			
	CN1	Bos et al., "PD153035, a Tyrosine Kinase Inhibitor, Prevents Epidermal Growth Factor Receptor Activation and Inhibits Growth of Cancer Cells in a Receptor Number-dependent Manner," <i>Clinical Cancer Research</i> , 3:2099-2106 (1997).			
	CO1	Boyd, W.A., et al., "Isolation and Characterization of a Novel Receptor-type Protein Tyrosine Kinase (hek) from a Human Pre-B Cell Line," <i>The Journal of Biological Chemistry</i> , 267(5):3262-3267 (1992).			
	CP1	Brehmer et al., "Cellular Targets of Gefitinib," <i>Cancer Research</i> , 65(2):379-382 (2005).			
	CQ1	Bruckner et al., "Tyrosine Phosphorylation of Transmembrane Ligands for Eph Receptors," <i>Science</i> , 275:1640-1643 (1997).			
	CR1	Chang, M.W., et al., "Adenovirus-Mediated Over-Expression of the Cyclin/Cyclin-Dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," <i>J. Clin. Invest.</i> , 96:2260-2268 (1995).			

Examiner Signature		Date Considered	8-11-06
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
Sheet	3	of	6	Attorney Docket Number	VASG-P01-002


CS1	Coffman, K.T., et al., "Differential EphA2 Epitope Display on Normal versus Malignant Cells," <i>Cancer Research</i> , 63:7907-7912 (2003).
CT1	Dodelet, V.C. et al., "Eph Receptors and Ephrin Ligands: Embryogenesis to Tumorigenesis," <i>Oncogene</i> , 19(49): 5614-19 (2000).
CU1	Durbin, L., et al., "Eph signaling is required for segmentation and differentiation of the somites," <i>Genes & Development</i> , 12:3096-3109 (1998).
CV1	Easty et al., "Abnormal Protein Tyrosine Kinase Gene Expression During Melanoma Progression and Metastasis," <i>Int. J. Cancer</i> , 60:129-136 (1995).
CW1	Easty et al., "Cytokine B61 as a growth factor for metastatic melanomas and increasing expression of its receptor ECK during melanoma progression," <i>Proceedings of the American Association for Cancer Research</i> , 35(356) (1994) abstract only.
CX1	Easty, et al., "Expression of Eck and Lerk-1 During Melanoma Progression," P137 St. George's Hospital Medical School, London, JK and Western Infirmary, Glasgow, UK, Collection of the National Library of Medicine by a third party.
CY1	Feldman, L.J., et al., "Perspectives of Arterial Gene Therapy for the Prevention of Restenosis," <i>Cardiovasc. Res.</i> , 32:194-207 (1996).
CZ1	Folkman et al., "Angiogenic Factors," <i>Science</i> , 235:442-447 (1987).
CA2	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Medicine</i> , 1: 27-31, (1995).
CB2	Folkman, J. et al., "Blood Vessel Formation: What Is Its Molecular Basis?" <i>Cell</i> , 87:1153-1155 (1996).
CC2	Folkman, J., "Angiogenic Therapy of the Human Heart," <i>Circulation</i> , 97(7): 628-29 (1998).
CD2	Folkman, J., "Antiangiogenic Gene Therapy," <i>Proc. Natl. Acad. Sci. USA.</i> , 95:9064-66 (1998).
CE2	Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," <i>Sci. Am.</i> , 275(3): 150-54 (1996).
CF2	Gale, N.W. et al., "Growth Factors Acting Via Endothelial Cell-Specific Receptor Tyrosine Kinases: VEGFs, Angiopoietins, and Ephrins in Vascular Development," <i>Genes Dev.</i> , 13:1055-66 (1999).
CG2	Gale, N.W., et al., "Ephrin-B2 Selectively Marks Arterial Vessels and Neovascularization Sites in the Adult, with Expression in Both Endothelial and Smooth-Muscle Cells," <i>Dev. Biol.</i> , 230: 151-160 (2001).
CH2	GenBank Accession No. P52803.
CI2	Genetech's Response to Final Office Action on U.S. Patent Application Serial No. 09/442,898, filed March 29, 2002.
CJ2	Glassberg et al., "Cultured endothelial cells derived from the human iliac arteries," <i>In Vitro</i> , 18:859-866 (1982).
CK2	Goetz et al., "Long-term serial cultivation of arterial and capillary endothelium from adult bovine brain," <i>In Vitro Cellular and Developmental Biology</i> , 21:172-180 (1985).
CL2	Guzman, R.J., et al., "In Vivo Suppression of Injury-Induced Vascular Smooth Muscle Cell Accumulation Using Adenovirus-Mediated Transfer of the Herpes Simplex Virus Thymidine Kinase Gene," <i>Proc. Natl. Acad. Sci. USA</i> , 91:10732-10736 (1994).
CM2	Hafner et al., "Differential Gene Expression of Eph Receptors and Ephrins in Benign Human Tissues and Cancers," <i>Clinical Chemistry</i> , 50(3):490-499 (2004).
CN2	Hafner, et al., "Loss of Eph B6 expression in metastatic melanoma," <i>International Journal of Oncology</i> , 23:1553-1559 (2003).
CO2	Hausner, C., "Organogenesis Vascular Graft Becomes Physiologically-Responsive Living

Examiner Signature		Date Considered	8.11.06
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
				Attorney Docket Number	VASG-P01-002
Sheet	4	of	6		

		Tissue After Implantation [online], <i>Nature Biotechnol.</i> , (1999).	
CP2	Henkemeyer, M., <i>et al.</i> , "Nuk Controls Pathfinding of Commissural Axons in the Mammalian Central Nervous System," <i>Cell</i> , 86:35-46 (1996).		
CQ2	Indolfi, C., <i>et al.</i> , "Inhibition of Cellular ras Prevents Smooth Muscle Cell Proliferation After Vascular Injury In Vivo," <i>Nature Med.</i> , 1(6):541-545 (1995).		
CR2	Kenyon, B.M., <i>et al.</i> , "A Model of Angiogenesis in the Mouse Cornea," <i>Invest Ophthalmol. Vis. Sci.</i> , 37:1625-1632 (1996).		
CS2	Keogh, M-C, <i>et al.</i> , "Design of a Muscle Cell-Specific Expression Vector Utilising Human Vascular Smooth Muscle ? - Actin Regulatory elements," <i>Gene Therapy</i> , 6:616-628 (1999).		
CT2	Lackmann, <i>et al.</i> , "Distinct Subdomains of the EphA3 Receptor Mediate Ligand Binding and Receptor Dimerization," <i>The Journal of Biological Chemistry</i> , 273 (32):20228-20237 (1998).		
CU2	Li, J., <i>et al.</i> , "Expression of the SM22x Promoter in Transgenic Mice Provides Evidence for Distinct Transcriptional Regulatory Programs in Vascular and Visceral Smooth Muscle Cells," <i>J. Cell Biol.</i> , 132:849-59 (1996).		
CV2	Lin, P., <i>et al.</i> , "Antiangiogenic Gene Therapy Targeting the Endothelium-Specific Receptor Tyrosine Kinase Tie2," <i>Proc. Natl. Acad. Sci., USA</i> , 95:8829-8834 (1998).		
CW2	Magal, <i>et al.</i> , "B61, a Ligand for the Eck Receptor Protein-Tyrosine Kinase, Exhibits Neurotrophic Activity in Cultures of Rat Spinal Cord Neurons," <i>Journal of Neuroscience Research</i> , 43:735-744 (1996).		
CX2	Maru, <i>et al.</i> , "Evolution, Expression, and Chromosomal Location of a Novel Receptor Tyrosine Kinase Gene, eph," <i>Molecular and Cellular Biology</i> , 8(9):3770-3776 (1998).		
CY2	Maru, <i>et al.</i> , "Overexpression confers an oncogenic potential upon the eph gene," <i>Oncogene</i> , 5:445-447 (1990).		
CZ2	Mellitzer, G., <i>et al.</i> , "Eph Receptors and Ephrins Restrict Cell Intermingling and Communication," <i>Nature</i> , 400:77-82 (1999).		
CA3	Nakanuma, Y. <i>et al.</i> , "Succinylated Wheat Germ Agglutinin Lectin Binding in Intrahepatic Vessels: A New Histochemical Tool," <i>Arch. Pathol. Lab. Med.</i> , 117:809-811 (1993).		
CB3	Niklason, L.E., <i>et al.</i> , "Functional Arteries Grown In Vitro," <i>Science</i> , 284:489-493 (1999).		
CC3	Niklason, L.E., <i>et al.</i> , "Morphologic and Mechanical Characteristics of Engineered Bovine Arteries," <i>J. Vasc. Surg.</i> , 33:628-638 (2001).		
CD3	Nikolova, <i>et al.</i> , "Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis," <i>Journal of Cell Science</i> , 111:2741-2751 (1998).		
CE3	Ogle <i>et al.</i> , "The Role of Vascular Smooth Muscle Cell Integrins in the Compaction and Mechanical Strengthening of a Tissue-Engineered Blood Vessel," <i>Tissue Engineering</i> , 5(4):387-402 (1999).		
CF3	Orioli, D., <i>et al.</i> , "Sek4 and Nuk Receptors Cooperate in Guidance of Commissural Axons and in Palate Formation," <i>Embo J.</i> , 15(22):6035-6049.		
CG3	Pandey <i>et al.</i> , "Role of B61, the ligand for the eck receptor tyrosine kinase, in TNF-a-induced angiogenesis" <i>Science</i> , 268:567-569 (1996).		
CH3	Parangi <i>et al.</i> , "Antiangiogenic therapy of transgenic mice impairs <i>de novo</i> tumor growth," <i>Proc. Natl. Acad. Sci. USA</i> , 93:2002-2007 (1996).		
CI3	Peng <i>et al.</i> , "Regulation of Ca ²⁺ -activated K ⁺ channels in pulmonary vascular smooth muscle cells: role of nitric oxide," <i>J. Applied Physiol.</i> , 81:1264-1272 (1996).		
CJ3	Presta <i>et al.</i> , "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders," <i>Cancer Research</i> , 57:4593-		

Examiner Signature		Date Considered	8-11-06
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/800350	
			Filing Date	March 12, 2004	
			First Named Inventor	Valery Krasnoperov	
			Art Unit	1642	
			Examiner Name	S. E. Aeder	
Sheet	5	of	6	Attorney Docket Number	VASG-P01-002

		4599 (1997).	
CK3	Ramchandran <i>et al.</i> , "Mettaloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells," <i>Am. J. Physiology</i> , 271:H744-751 (1996).		
CL3	Risau, W., "Mechanisms of angiogenesis," <i>Nature</i> , 386:671-674 (1997).		
CM3	Shepard, <i>et al.</i> , "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," <i>Journal of Clinical Immunology</i> , 11(3):117-127 (1991).		
CN3	Simonet, S., <i>et al.</i> , "Venous and Arterial Endothelial Cells Respond Differently to Thrombin and its Endogenous Receptor Agonist," <i>European Journal of Pharmacology</i> , 216:135-137 (1992).		
CO3	Simons, M., <i>et al.</i> , "Antisense c-myb Oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation In Vivo," <i>Nature</i> , 359(6390):67-70 (1992).		
CP3	Stein, E. <i>et al.</i> , "Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses," <i>Genes & Development</i> , 12:667-678 (1998).		
CQ3	Stein, E. <i>et al.</i> , "Nck Recruitment to Eph Receptor, EphB1/ELK, Couples Ligand Activation to c-Jun Kinase," <i>The Journal of Biological Chemistry</i> , 273(3):1303-1308 (1998).		
CR3	Sturz, <i>et al.</i> , "EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration," <i>Biochemical and Biophysical Research Communications</i> , 313:80-88 (2004).		
CS3	Sunasse, <i>et al.</i> , "Tumour angiogenesis: Hitting cancer where it hurts," <i>Current Biology</i> , 7(5):R282-R285 (1997).		
CT3	Tallquist, M.D., <i>et al.</i> , "Growth Factor Signaling Pathways in Vascular Development," <i>Oncogene</i> , 18(55):7917-7932 (1999).		
CU3	The Eph Nomenclature Committee, "Unified Nomenclature for Eph Family Receptors and Their Ligands, the Ephrins," <i>Cell</i> , 90:403-404 (1997).		
CV3	Thurston <i>et al.</i> , "Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding," <i>American Journal of Physiology</i> , 271:H2547-H2562 (1996).		
CW3	Tsui, L.V., <i>et al.</i> , "p27-p16 Fusion Gene Inhibits Angioplasty-Induced Neointimal Hyperplasia and Coronary Artery Occlusion," <i>Circ. Res.</i> , 89:323-328 (2001).		
GX3	Twardowski <i>et al.</i> , "Clinical trials of antiangiogenic agents," <i>Current Opinion in Oncology</i> , 9:584-589 (1997).		
CY3	van de Wiel <i>et al.</i> , "Factors that define the susceptibility of endothelial cells to tumor necrosis factor and lipid A," <i>Immunopharmacology</i> , 23:49-56 (1992).		
CZ3	Vasgene Therapeutics, Inc., "Statement of Grounds of Opposition," In the Matter of European Patent No. 1135153 (EP-B-1135153), (2006).		
CA4	Vector Laboratories, "Wheat Germ Agglutinin (WGA)," [online]		
CB4	von der Leyen, H.E., <i>et al.</i> , "Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene," <i>Proc. Natl. Acad. Sci.</i> , 92:1137-1141 (1995).		
CC4	Wang <i>et al.</i> , "Molecular Distinction and Angiogenic Interactions Between Embryonic Arteries and Veins Revealed By EphrinB2 and Its Receptor EphB4," <i>Circulation: Melvin L. Marcus Young Investigator Award</i> , Abstract 341.		
CD4	Wang, H. U. <i>et al.</i> , "Eph Family Transmembrane Ligands Can Mediate Repulsive Guidance of Trunk Neural Crest Migration and Motor Axon Outgrowth," <i>Neuron</i> , 18:383-396 (1997).		
CE4	Waugh, J.M., <i>et al.</i> , "Thrombomodulin Overexpression to Limit Neointima Formation," <i>Circulation</i> , 102:332-337 (2000).		
CF4	Winlaw, "Angiogenesis in the Pathobiology and Treatment of Vascular and Malignant		

Examiner Signature		Date Considered	8-11-06
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
Sheet	6	of	6	Attorney Docket Number	VASG-P01-002

		Diseases," <i>Ann. Thorac. Surg.</i> , 64:1204-1211 (1997).	
	CG4	Xu, <i>et al.</i> , "Function of the Eph-related kinase rtk1 in patterning of the zebrafish forebrain," <i>Nature</i> , 381:19-322 (1996).	
	CH4	Yamamoto <i>et al.</i> , "Differences in Cellular Responses to Mitogens in Arterial Smooth Muscle Cells Derived From Patients With Moyamoya Disease," <i>Stroke</i> , 29:1188-1193 (1998).	
	CI4	Yancopoulos, G. D. <i>et al.</i> , "Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border," <i>Cell</i> , 93:661-664 (1998).	
	CJ4	Yuan, <i>et al.</i> , "Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis," <i>Blood</i> , 104(4):1025-1033 (2004).	
	CK4	Zetter, "Angiogenesis and Tumor Metastasis," <i>Annu. Rev. Med.</i> , 49:407-424, (1998).	
	CL4	Zhang, X-Q, <i>et al.</i> , "Stromal Cells Expressing ephrin-B2 Promote the Growth and Sprouting of Ephrin-B2+ Endothelial Cells," <i>Blood</i> , 98:1028-37 (2001).	
	CM4	Zhou, "The Eph Family Receptor and Ligands," <i>Pharmacol. Ther.</i> , 77(3) 151-181 (1998).	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	8.11.06
-----------------------	---	--------------------	---------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/800,350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
Sheet	1	of	1	Attorney Docket Number	VASG-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Dermer, G., "Another Anniversary for the War on Cancer," <u>Bio/Technology</u> , 12:320 (1994).	
	CB	Freshney, R. Ian, <u>Culture of Animal Cells: A Manual of Basic Technique</u> , Alan R. Liss, Inc. (1983).	
	CC	Gura, T., "Systems for Identifying New Drugs Are Often Faulty," <u>Science</u> , 278:1041-1042 (1997).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	8-11-06
-----------------------	--	--------------------	---------